« Back
Home /
EHP-101 (VCE- 004.8)

EHP-101 (VCE- 004.8)

Item no.	DCC-DC57061-1g
Manufacturer	DCChemicals
CASRN	1818428-24-8
Amount	1 g
Quantity options	100 mg 1 g 250 mg
Category	Reagents & Chemicals Molecules
Type	Chemicals
Applications	EHP-101 (VCE-004.8) is an orally active, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice., specific PPARγ and CB2 receptor dual agonist. EHP-101 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. EHP-101 (20 mg/kg/day; i.p.; for 3 weeks) induces a significant red
Specific against	other
Smiles	CCCCCC1=C(NCC2=CC=CC=C2)C(O)=C(C(=O)C1=O)[C@H]3[C@@H](CCC(C)=C3)C(C)=C
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Available
Manufacturer - Applications	EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. EHP-101 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. EHP-101 (20 mg/kg/day; i.p.; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice.
Molecular Weight	433, 5824

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 g

available

Delivery expected until 11/13/2025

Express Delivery: Save 3 days

Compare

Add to wishlist

Get an offer